Among the top five EGFR inhibitors identified, afatinib, a second generation EGFR inhibitor approved by FDA for cancer treatment, was the top-ranking drug in the enrichment analyses that were included in multiple pathways involved in the pathogenesis of NIHL. This evidence concerns the gene EGFR and cancer.